NEW YORK, Oct. 11, 2016 /PRNewswire/ -- Rosen Law
Firm, a global investor rights law firm, reminds purchasers of
Seres Therapeutics, Inc. securities (NASDAQ: MCRB) from
June 25, 2015 through July 29, 2016, both dates inclusive (the "Class
Period") of the important November 28,
2016 lead plaintiff deadline in the class action. The
lawsuit seeks to recover damages for Seres Therapeutics investors
under the federal securities laws.
To join the Seres Therapeutics class action, go to the firm's
website at http://rosenlegal.com/cases-961.html or call
Phillip Kim, Esq. or Kevin Chan, Esq. toll free at 866-767-3653 or
email pkim@rosenlegal.com or kchan@rosenlegal.com for more
information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A
CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU
RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO
NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period defendants
issued false and misleading statements to investors that Seres
Therapeutics advertised and hyped its lead drug product candidate
SER-109 as "novel class of biological drugs" and a potential
"first-in-field drug" despite knowledge that the Phase 2 clinical
trial of SER-109 would fail to achieve its primary endpoint as
compared to placebo. When the true details entered the market, the
lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to
serve as lead plaintiff, you must move the Court no later than
November 28, 2016. A lead plaintiff
is a representative party acting on behalf of other class members
in directing the litigation. If you wish to join the litigation, go
to the firm's website at http://rosenlegal.com/cases-961.html for
more information. You may also contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at
866-767-3653 or via email at pkim@rosenlegal.com or
kchan@rosenlegal.com. Attorney Advertising. Prior results do
not guarantee a similar outcome.
Follow us for updates on LinkedIn:
https://www.linkedin.com/company/the-rosen-law-firm or on Twitter:
https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe,
concentrating its practice in securities class actions and
shareholder derivative litigation.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
Kevin Chan, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 34th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
kchan@rosenlegal.com
www.rosenlegal.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/mcrb-loss-notice-rosen-law-firm-reminds-seres-therapeutics-inc-investors-of-important-deadline-in-lawsuit---mcrb-300342971.html
SOURCE Rosen Law Firm, P.A.